New Diagnostic Criteria to See How HCC Nodules Respond After Ablation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with hepatocellular carcinoma who have undergone locoregional thermal ablation (RFA or MWA). It evaluates the use of contrast-enhanced ultrasound, guided by the updated CEUS LI-RADS TRA criteria, to assess treatment response after ablation. The goal is to determine how well this imaging approach reflects residual disease or successful ablation, guiding subsequent management. Eligible participants are adults with prior RFA or MWA treatment and who consent to post-treatment CEUS and follow-up CT or MRI imaging. Data will be collected from a single or few centers in Rome, Italy, under the coordination of the Fondazione Policlinico Universitario A. Gemelli IRCCS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age greater than 18 years;
* HCC nodules treated with locoregional thermal ablation using RFA or MWA;
* Signed informed consent.

Exclusion Criteria:

* Refusal to participate in the study;
* Contraindications to performing post-treatment CEUS;
* Absence of at least one CEUS examination during follow-up after locoregional thermal ablation with RFA or MWA;
* Contraindications to performing post-treatment CT or MRI.
* Absence of post-treatment CT or MRI follow-up imaging;
* LR-TRA Nonevaluable categorization on post-treatment CT or MRI follow-up imaging.

Where it's running

• Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italia
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Laura Riccardi — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Laura Riccardi
• Email: laura.riccardi@policlinicogemelli.it
• Phone: +39-0630155079

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.